Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination

Health Behavior Clinical Trial

Official title:

Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02897232
• Other study ID #: STUDY00000618
• Status: Completed
• Start date: July 2016
• Est. completion date: April 2020

Study information

• Verified date: February 2021
• Source: Louisiana State University Health Sciences Center Shreveport
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify barriers which prevent these groups from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection. The research is focused on these questions: Do community members understand the ease of transmission of the HPV virus in males 9-26? Do community members, physicians, residents and medical students have knowledge of the associated diseases that may occur with the HPV virus infection in males age 9-26? Do community members, physicians, residents and medical students know the ages in which males should receive the HPV vaccine three-shot series? What barriers prevent community members and physicians, residents and medical students from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection?

Description:

This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify barriers which prevent these groups from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection. The research is focused on these questions: Do community members understand the ease of transmission of the HPV virus in males 9-26? Do community members, physicians, residents and medical students have knowledge of the associated diseases that may occur with the HPV virus infection in males age 9-26? Do community members, physicians, residents and medical students know the ages in which males should receive the HPV vaccine three-shot series? What barriers prevent community members and physicians, residents and medical students from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection?

Recruitment information / eligibility

• Status: Completed
• Enrollment: 386
• Est. completion date: April 2020
• Est. primary completion date: March 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Community Participants Inclusion All visitors to the Pediatric or Internal Medicine University Health Shreveport Clinics willing to complete a survey Community Study Exclusion Those do not wish to participate in the study Those who English is not their first language Clinical Faculty, Resident, and Medical Student Study Inclusion All Louisiana State University Shreveport Health Clinical Faculty, Resident, and Medical Student Inclusion willing to to complete the online survey. Clinical Faculty, Resident, and Medical Student Study Exclusion Any LSU Health Shreveport Clinical Faculty, Resident, and Medical Student which declines to take the survey or do not attempt to complete it.

Related Conditions & MeSH terms

• Attitude of Health Personnel
• Health Behavior
• Human Papilloma Virus, Male
• Papilloma
• Papillomavirus Infections

Intervention

Other:
• Survey
Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination

Locations

Country	Name	City	State
United States	Louisiana State University Health	Shreveport	Louisiana

Sponsors (1)

Lead Sponsor	Collaborator
Louisiana State University Health Sciences Center Shreveport

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Barriers to HPV Vaccination	What are the barriers which prevent community members and physicians, residents and medical students from ensuring that males age 9-26 are vaccinated with the HPV three-shot vaccination.	60 days
Secondary	Knowledge pertaining to ease of Human Papillomavirus transmission.	Do community members and physicians understand the ease of HPV transmission?	60 days
Secondary	Knowledge of Associated HPV diseases	Do community member and physicians know the associated HPV diseases?	60 days
Secondary	Knowledge of age in which males should be vaccinated against HPV.	Do community member and physicians know the age in which males should be vaccinated against HPV?	60 days